title: Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
abstract: Intravenous romidepsin (Istodax®), a histone deacetylase inhibitor, is indicated in the US for the treatment of cutaneous T-cell lymphoma (CTCL) in adults who have received at least one prior systemic therapy. In two noncomparative trials in adults with relapsed, refractory, and/or advanced CTCL, romidepsin was associated with an overall response (i.e. complete or partial response) rate of 34% and 35%, and a complete response rate of 6% (in both trials). Romidepsin had an acceptable tolerability profile, with the most common grade 3 or 4 adverse events considered at least possibly related to romidepsin being hematologic or asthenic in nature.
authors: Adis, Auckland, New Zealand. demail@adis.co.nz
authors: Katherine A
authors: KA
authors: Lyseng-Williamson
authors: Lily P H
authors: LP
authors: Yang
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use*; D047630:Depsipeptides / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; C087123:romidepsin